[Hypereosinophilic syndrome in acute lymphatic leukemia]. 1986

D Nadal, and H J Plüss, and W Jörg, and W H Hitzig

Acute lymphatic leukemia (common-ALL-Ag positive) was found to be the underlying disease in a 4-year-old boy with arthropathy, generalized rash and marked eosinophilia. ALL may be overlooked in the early stages. Cytochemical, chromosomal and immunological markers are needed to distinguish it from other leukemias. As shown by the data of 25 patients from the literature, hypereosinophilic syndrome (HES) influences morbidity and lethality. Hydroxyurea rapidly lowers the eosinophil counts and may therefore prevent the cardiac involvement typical of HES.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004802 Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs. Eosinophilia, Tropical,Hypereosinophilia,Tropical Eosinophilia,Hypereosinophilias,Tropical Eosinophilias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D013577 Syndrome A characteristic symptom complex. Symptom Cluster,Cluster, Symptom,Clusters, Symptom,Symptom Clusters,Syndromes

Related Publications

D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
January 1993, Acta haematologica,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
September 1984, Cancer,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
April 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
May 2000, Annals of hematology,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
June 1991, International journal of hematology,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
January 1992, Pediatric hematology and oncology,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
November 1976, The Journal of pediatrics,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
July 1983, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
January 1995, Acta haematologica Polonica,
D Nadal, and H J Plüss, and W Jörg, and W H Hitzig
January 2008, Cancer treatment and research,
Copied contents to your clipboard!